Dr. Sulaiman Al Habib Medical Services Group (SASE:4013) - Share price, News & Analysis

Q: What is the Fair Price of 4013 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

4013 (SAR210.2) is trading above our estimate of [[fair value]] (SAR186.74)

4013 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	6/6
Financial Health	5/6
Dividends	1/6

4013 Stock Overview

Rewards

Earnings are forecast to grow 10.52% per year

Earnings grew by 20.6% over the past year

Risk Analysis

No risks detected for 4013 from our risk checks.

Dr. Sulaiman Al Habib Medical Services Group Competitors

Mouwasat Medical Services

SASE:4002

ر.س23.5b

Dallah Healthcare

SASE:4004

ر.س10.5b

Al Hammadi Company For Development and Investment

SASE:4007

ر.س6.6b

Middle East Healthcare

SASE:4009

ر.س3.1b

Price History & Performance

Summary of all time highs, changes and price drops for Dr. Sulaiman Al Habib Medical Services Group
Historical stock prices
Current Share Price	ر.س210.20
52 Week High	ر.س230.00
52 Week Low	ر.س148.00
Beta	0.94
1 Month Change	4.68%
3 Month Change	-3.13%
1 Year Change	14.86%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	292.16%

Recent News & Updates

Aug 08

Why Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Could Be Worth Watching

Let's talk about the popular Dr. Sulaiman Al Habib Medical Services Group Company ( TADAWUL:4013 ). The company's...

Jul 12

Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Has More To Do To Multiply In Value Going Forward

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...

May 31

Does Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Deserve A Spot On Your Watchlist?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

May 17

A Look At The Fair Value Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013)

Today we will run through one way of estimating the intrinsic value of Dr. Sulaiman Al Habib Medical Services Group...

Shareholder Returns

	4013	SA Healthcare	SA Market
7D	-2.6%	-3.0%	-2.0%
1Y	14.9%	15.1%	19.2%

Return vs Industry: 4013 matched the SA Healthcare industry which returned 15.1% over the past year.

Return vs Market: 4013 underperformed the SA Market which returned 19.2% over the past year.

Price Volatility

Is 4013's price volatile compared to industry and market?
4013 volatility
4013 Average Weekly Movement	3.2%
Healthcare Industry Average Movement	4.6%
Market Average Movement	4.9%
10% most volatile stocks in SA Market	8.2%
10% least volatile stocks in SA Market	3.1%

Stable Share Price: 4013 is less volatile than 75% of SA stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 4013's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1993	n/a	Nasser Mohammed Al Haqbani	https://www.hmg.com

Dr. Sulaiman Al Habib Medical Services Group Company establishes, manages, and operates hospitals, general and specialized medical complexes, day surgery centers, and pharmaceutical facilities in Saudi Arabia. The company operates maternity, and orthopedics and spinal surgeries hospitals. It also operates dermatology, plastic surgery, ophthalmology, obesity treatment, and fertility centers, as well as pharmacies.

Dr. Sulaiman Al Habib Medical Services Group Fundamentals Summary

How do Dr. Sulaiman Al Habib Medical Services Group's earnings and revenue compare to its market cap?
4013 fundamental statistics
Market Cap	ر.س73.57b
Earnings (TTM)	ر.س1.52b
Revenue (TTM)	ر.س7.81b

48.4x

P/E Ratio

9.4x

P/S Ratio

Is 4013 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
4013 income statement (TTM)
Revenue	ر.س7.81b
Cost of Revenue	ر.س5.26b
Gross Profit	ر.س2.55b
Other Expenses	ر.س1.02b
Earnings	ر.س1.52b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	4.35
Gross Margin	32.59%
Net Profit Margin	19.47%
Debt/Equity Ratio	55.6%

How did 4013 perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

71%

Payout Ratio

We’ve recently updated our valuation analysis.

Valuation

Is 4013 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4013?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 4013. This is calculated by dividing 4013's market cap by their current preferred multiple.
What is 4013's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	ر.س73.57b

4013 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	9.5x
Enterprise Value/EBITDA	39.8x
PEG Ratio	4.6x

Price to Earnings Ratio vs Peers

How does 4013's PE Ratio compare to its peers?

4013 PE Ratio vs Peers

The above table shows the PE ratio for 4013 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PE	Estimated Growth	Market Cap
Peer Average	59.5x
4002 Mouwasat Medical Services	40.4x	13.6%	ر.س23.5b
4004 Dallah Healthcare	36.5x	14.6%	ر.س10.5b
4007 Al Hammadi Company For Development and Investment	45.8x	5.0%	ر.س6.6b
4009 Middle East Healthcare	115.2x	32.7%	ر.س3.1b
4013 Dr. Sulaiman Al Habib Medical Services Group	48.4x	10.5%	ر.س73.6b

Price-To-Earnings vs Peers: 4013 is good value based on its Price-To-Earnings Ratio (48.4x) compared to the peer average (59.5x).

Price to Earnings Ratio vs Industry

How does 4013's PE Ratio compare vs other companies in the Asian Healthcare Industry?

Price-To-Earnings vs Industry: 4013 is expensive based on its Price-To-Earnings Ratio (48.4x) compared to the SA Healthcare industry average (38.5x)

Price to Earnings Ratio vs Fair Ratio

What is 4013's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4013 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	48.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4013's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of 4013 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4013 (SAR210.2) is trading above our estimate of fair value (SAR186.74)

Significantly Below Fair Value: 4013 is trading above our estimate of fair value.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Future Growth

How is Dr. Sulaiman Al Habib Medical Services Group forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

10.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4013's forecast earnings growth (10.5% per year) is above the savings rate (8.9%).

Earnings vs Market: 4013's earnings (10.5% per year) are forecast to grow faster than the SA market (0.9% per year).

High Growth Earnings: 4013's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4013's revenue (13.1% per year) is forecast to grow faster than the SA market (-1.6% per year).

High Growth Revenue: 4013's revenue (13.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4013's Return on Equity is forecast to be high in 3 years time (28.5%)

Discover growth companies

Past Performance

How has Dr. Sulaiman Al Habib Medical Services Group performed over the past 5 years?

Past Performance Score

6/6

Past Performance Score 6/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

19.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 4013 has high quality earnings.

Growing Profit Margin: 4013's current net profit margins (19.5%) are higher than last year (18.7%).

Past Earnings Growth Analysis

Earnings Trend: 4013's earnings have grown by 19% per year over the past 5 years.

Accelerating Growth: 4013's earnings growth over the past year (20.6%) exceeds its 5-year average (19% per year).

Earnings vs Industry: 4013 earnings growth over the past year (20.6%) exceeded the Healthcare industry 0.6%.

Return on Equity

High ROE: 4013's Return on Equity (26.6%) is considered high.

Discover strong past performing companies

Financial Health

How is Dr. Sulaiman Al Habib Medical Services Group's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: 4013's short term assets (SAR4.4B) exceed its short term liabilities (SAR2.2B).

Long Term Liabilities: 4013's short term assets (SAR4.4B) exceed its long term liabilities (SAR3.8B).

Debt to Equity History and Analysis

Debt Level: 4013's net debt to equity ratio (7.6%) is considered satisfactory.

Reducing Debt: 4013's debt to equity ratio has increased from 26.6% to 55.6% over the past 5 years.

Debt Coverage: 4013's debt is well covered by operating cash flow (69.9%).

Interest Coverage: 4013's interest payments on its debt are well covered by EBIT (56.8x coverage).

Balance Sheet

Discover healthy companies

Dividend

What is Dr. Sulaiman Al Habib Medical Services Group current dividend yield, its reliability and sustainability?

Dividend Score

1/6

Dividend Score 1/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

1.64%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 4013's dividend (1.64%) isn’t notable compared to the bottom 25% of dividend payers in the SA market (1.86%).

High Dividend: 4013's dividend (1.64%) is low compared to the top 25% of dividend payers in the SA market (4.2%).

Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 4013 has been paying a dividend for less than 10 years.

Growing Dividend: 4013's dividend payments have increased, but the company has only paid a dividend for 2 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (71.1%), 4013's dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (126%), 4013's dividend payments are not well covered by cash flows.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.6yrs

Average management tenure

CEO

Nasser Mohammed Al Haqbani

no data

Tenure

ر.س230,000

Compensation

Mr. Nasser Mohammed Abdulaziz Al Haqbani has been Chief Executive Officer and Executive Member of Board at Dr. Sulaiman Al Habib Medical Services Group Company since December 10, 2018 and also serves as it...

Leadership Team

Experienced Management: 4013's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

Experienced Board: 4013's board of directors are considered experienced (3.7 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/08/19 00:00
End of Day Share Price	2022/08/18 00:00
Earnings	2022/06/30
Annual Earnings	2021/12/31